Streetbeat News

Regulatory

PDD

PDD shares are trading lower due to a report that US lawmakers are urging government agencies to limit the company's product exports to the US. This development could potentially impact PDD's revenue and market presence in the US, leading to investor concerns over future growth prospects.

Portfolio Pulse from Luke J Jacobi

February 26, 2024 | 1:24 pm

TEVA

Teva Pharmaceutical Industries Ltd. shares are experiencing an uptick following the announcement of FDA approval for its new arthritis treatment.

Portfolio Pulse from Luke J Jacobi

February 26, 2024 | 1:22 pm

HOTH

Hoth Therapeutics has partnered with Altasciences to conduct a study on HT-KIT, a therapeutic aimed at fighting mast cell-derived cancers. HT-KIT has been granted FDA Orphan Drug Status due to its potential benefits and has shown positive results in previous studies.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:12 pm

T

AT&T Inc (NYSE:T) announced a $5 credit for customers affected by a nationwide network outage last week, excluding business accounts and prepaid services like Cricket Wireless. CEO John Stankey stated the cost is manageable and won't affect 2024 goals or financial guidance. The outage, caused by an incorrect process during network expansion, prompted an FCC investigation. Despite the disruption, AT&T's Q4 2023 revenues were up 2.2% YOY, and shares rose 0.12% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

February 26, 2024 | 1:12 pm

BYSI

BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company, has regained compliance with Nasdaq's minimum bid price and periodic filing requirements. The company received notifications from Nasdaq confirming that it met the minimum bid price requirement for 10 consecutive business days and complied with the periodic filing requirement by filing its Form 6-K for the period ended June 30, 2023.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:05 pm

SVFD

Save Foods, Inc. (NASDAQ:SVFD), an Agri-Food Tech company, has commenced commercial activities in Brazil through an exclusive local distributor, following compliance with local regulations. This move capitalizes on Brazil's significant growth in fruit exports, which saw a 6% increase in 2023, reaching 1.06 million tons. Save Foods' eco crop protection solution aims to support Brazilian packers in meeting EU market standards, particularly the EU's residue limits. The partnership with the distributor is expected to enhance the post-harvest treatment of fresh produce, starting with limes and mangos, benefiting farmers, distributors, and consumers.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:01 pm

ALVO

TEVA

The FDA approved Simlandi, an interchangeable biosimilar to AbbVie's Humira, developed by Alvotech and marketed by Teva Pharmaceutical Industries. This approval could impact the arthritis drug market, particularly affecting AbbVie's dominance.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:23 pm

NTRA

The Centers For Medicare & Medicaid Services (CMS) has expanded coverage for Natera's Signatera Molecular Residual Disease Test to include ovarian cancer and neoadjuvant breast cancer. This decision broadens the potential patient base for Natera's diagnostic test, potentially increasing its usage and revenue from these additional cancer types.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:11 pm

MIST

Milestone Pharmaceuticals plans to resubmit the NDA for Etripamil to the FDA for Paroxysmal Supraventricular Tachycardia after addressing concerns from a Refusal to File letter. The FDA indicated that the timing of adverse events had minimal impact on the safety profile of Etripamil, and the company will restructure and reformat data sets for resubmission.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:06 pm

BGNE

The European Medicines Agency's Committee For Medicinal Products For Human Use recommended approval of BeiGene's Tislelizumab for treating non-small cell lung cancer (NSCLC) in three specific indications. These include combinations with chemotherapy for first-line treatment in both squamous and non-squamous NSCLC, and as monotherapy for patients who have previously undergone platinum-based therapy.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 10:03 am